Grupo de Investigación

Información no disponible

Ø Búsqueda de predictores de respuesta a quimioterapia neoadyuvante con docetaxel-carboplatino en pacientes con cáncer de mama Triple Negativo.
Ø Desarrollo de biopsia líquida y evolución dinámica del Cáncer. Estudios en cáncer de mama metastásico, Cáncer Colorrectal, Hepatocarcinoma y Colangiocarcinoma
Ø Generación de modelos preclínicos y estudios con PDXs. Estudios para la identificación de predictores de respuesta al tratamiento, sensibilidades a fármacos, desarrollo de metástasis y efectos en vías de señalización.
Ø Proyectos Traslacionales asociados a Ensayos Clínicos. Evaluación de nuevas terapias y Resistencia a fármacos.
Ø Desarrollo de nuevas terapias dirigidas e inmunes para pacientes con cáncer de mama luminal, positivo para HER2 y/o triples negativo

Las 10 primeras publicaciones según Factor de impacto (F.I.) de los últimos 4 años:

Hortobagyi G.N., Lacko A., Sohn J., Cruz F., Ruiz Borrego M., Manikhas A. et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Annals of Oncology. 2024;.
PUBMED DOI
Martin M., Stecklein S.R., Gluz O., Villacampa G., Monte-Millan M., Nitz U. et al. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Annals of Oncology. 2024;.
PUBMED DOI
Villacampa G., Tung N.M., Pernas S., Pare L., Bueno-Muino C., Echavarria I. et al. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer. Annals of Oncology. 2023;34(9):783-795.
PUBMED DOI
Jhaveri K., Eli L.D., Wildiers H., Hurvitz S.A., Guerrero-Zotano A., Unni N. et al. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Annals of Oncology. 2023;34(10):885-898.
PUBMED DOI
Loibl S., Martin M., Bonnefoi H., Untch M., Kim S.-B., Bear H.D. et al. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy—PENELOPE-B. Annals of Oncology. 2025;.
PUBMED DOI
Johnston S.R.D., Toi M., O'Shaughnessy J., Rastogi P., Campone M., Neven P. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2022;.
PUBMED DOI
Denkert C., Rachakonda S., Karn T., Weber K., Martin M., Marme F. et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping. Cancer Cell. 2025;43(2):232-247.e4.
PUBMED DOI
Rastogi P., O'shaughnessy J., Martin M., Boyle F., Cortes J., Rugo H.S. et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of Clinical Oncology. 2024;42(9):987-993.
PUBMED DOI
Arance A., de la Cruz-Merino L., Petrella T.M., Jamal R., Ny L., Carneiro A. et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41(1):75-85.
PUBMED DOI
Kok M., Gielen R.-J., Adams S., Lennerz J.K., Sharma P., Loibl S. et al. Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer. Journal of Clinical Oncology. 2024;.
PUBMED DOI